201 related articles for article (PubMed ID: 35245103)
1. Aprocitentan and the endothelin system in resistant hypertension.
Clozel M
Can J Physiol Pharmacol; 2022 Jul; 100(7):573-583. PubMed ID: 35245103
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M
J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171
[TBL] [Abstract][Full Text] [Related]
3. Aprocitentan: A new development of resistant hypertension.
Yao Y; Fan B; Yang B; Jia Z; Li B
J Clin Hypertens (Greenwich); 2023 Jul; 25(7):587-590. PubMed ID: 37334561
[TBL] [Abstract][Full Text] [Related]
4. Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential.
Xu J; Jiang X; Xu S
Drug Discov Today; 2023 Nov; 28(11):103788. PubMed ID: 37742911
[TBL] [Abstract][Full Text] [Related]
5. Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension.
McCoy EK; Lisenby KM
J Cardiovasc Pharmacol; 2021 Jun; 77(6):699-706. PubMed ID: 34001723
[TBL] [Abstract][Full Text] [Related]
6. Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension.
Heidari Nejad S; Azzam O; Schlaich MP
Curr Hypertens Rep; 2023 Oct; 25(10):343-352. PubMed ID: 37566184
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension.
Brussee JM; Sidharta PN; Dingemanse J; Krause A
J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):243-252. PubMed ID: 38332190
[TBL] [Abstract][Full Text] [Related]
8. Endothelin and endothelin antagonists in hypertension.
Schiffrin EL
J Hypertens; 1998 Dec; 16(12 Pt 2):1891-5. PubMed ID: 9886874
[TBL] [Abstract][Full Text] [Related]
9. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
Sidharta PN; Dingemanse J
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
[TBL] [Abstract][Full Text] [Related]
10. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
Sidharta PN; Ulč I; Dingemanse J
Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
[TBL] [Abstract][Full Text] [Related]
11. New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis.
Mahfooz K; Najeed S; Tun HN; Khamosh M; Grewal D; Hussain A; Ong K; Dharmarajan L; Vasavada A
Curr Probl Cardiol; 2023 Jul; 48(7):101686. PubMed ID: 36893968
[TBL] [Abstract][Full Text] [Related]
12. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats.
Park JB; Schiffrin EL
Hypertension; 2001 Jun; 37(6):1444-9. PubMed ID: 11408393
[TBL] [Abstract][Full Text] [Related]
13. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.
Schiffrin EL; Turgeon A; Deng LY
Br J Pharmacol; 1997 Jul; 121(5):935-40. PubMed ID: 9222550
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive effects of a mixed endothelin-A- and -B-receptor antagonist, J-104132, were augmented in the presence of an AT1 -receptor antagonist, MK-954.
Ikeda T; Ohta H; Okada M; Kawai N; Nakao R; Siegl PK; Kobayashi T; Miyauchi T; Nishikibe M
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S337-41. PubMed ID: 11078414
[TBL] [Abstract][Full Text] [Related]
15. Endothelin-1, endothelin receptor antagonists, and vein graft occlusion in coronary artery bypass surgery: 20 years on and still no journey from bench to bedside.
Dashwood MR; Loesch A
Can J Physiol Pharmacol; 2020 Sep; 98(9):570-578. PubMed ID: 32343914
[TBL] [Abstract][Full Text] [Related]
16. Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans.
Sidharta PN; Fischer H; Dingemanse J
Curr Drug Metab; 2021; 22(5):399-410. PubMed ID: 33563190
[TBL] [Abstract][Full Text] [Related]
17. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.
Danaietash P; Verweij P; Wang JG; Dresser G; Kantola I; Lawrence MK; Narkiewicz K; Schlaich M; Bellet M;
J Clin Hypertens (Greenwich); 2022 Jul; 24(7):804-813. PubMed ID: 35686330
[TBL] [Abstract][Full Text] [Related]
18. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
Sidharta PN; Melchior M; Kankam MK; Dingemanse J
Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
[TBL] [Abstract][Full Text] [Related]
19. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects.
Fontes MSC; Dingemanse J; Sidharta PN
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):718-725. PubMed ID: 33063477
[TBL] [Abstract][Full Text] [Related]
20. Endothelin System in Hypertension and Chronic Kidney Disease.
Schiffrin EL; Pollock DM
Hypertension; 2024 Apr; 81(4):691-701. PubMed ID: 38059359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
